ClinicalTrials.gg
CompletedNCT05368285Updated Mar 26, 2025

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

A Phase 2 interventional study of barzolvolimab and Matching Placebo in Chronic Spontaneous Urticaria, sponsored by Celldex Therapeutics. Completed at 56 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Celldex Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.

Enrollment
21st of 58
208 · median 132
Started
2022
with 4 others
Phase 2
23 of 64
4 open now
Registered
35th of 64
by date
Lead sponsor
5 of 64
Celldex Therapeutics

Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 21st largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2022, is one of 23 in phase 2, and was the 35th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Chronic Urticaria with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria

Read the detailed description

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab in patients with Chronic Spontaneous Urticaria.

There is a screening period of up to 4 weeks, followed by a 16-week placebo-controlled treatment period (Placebo-Controlled Treatment Phase) where patients will receive either barzolvolimab at a dose level of 75mg, 150mg, or 300mg, or placebo, and then a 36-week treatment period where all patients will receive barzolvolimab. Patients who receive barzolvolimab 75mg or placebo in the placebo-controlled treatment phase will be re-randomized to receive either barzolvolimab 150mg or 300mg in the active treatment phase.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • CDX-0159
  • barzolvolimab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  1. Males and females, >/= 18 years of age.
  2. Diagnosis of chronic spontaneous urticaria (CSU) >/= 6 months.
  3. Diagnosis of CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:

    1. The presence of hives for >/= 6 weeks at any time prior to Visit 1 despite the use of H1-antihistamines.
    2. Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.
    3. UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to treatment.
  4. Normal blood counts and liver function tests
  5. Both males and females of must agree to use highly effective during the study and for 150 days after treatment.
  6. Willing and able to complete a daily symptom electronic diary and comply with study visits.

Key exclusion criteria:

  1. Women who are pregnant or nursing.
  2. Clearly defined cause for chronic urticaria.
  3. Active, pruritic skin condition in addition to CSU.
  4. Medical condition that would cause additional risk or interfere with study procedures.
  5. Known active , or infection.
  6. Vaccination of a within 2 months prior to study treatment (subjects must agree to avoid vaccination during the study). Inactivated vaccines are allowed such as seasonal influenza injection or COVID-19 vaccine.
  7. History of anaphylaxis
  8. Prior treatment with barzolvolimab

There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    barzolvolimab 75 mg then 150 mg

    barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 150 mg injection subcutaneous every 4 weeks for 36 weeks

    Biological: barzolvolimab

  • Experimental
    barzolvolimab 75 mg then 300 mg

    barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 300 mg injection subcutaneous every 8 weeks for 36 weeks

    Biological: barzolvolimab

  • Experimental
    barzolvolimab 150 mg

    barzolvolimab 150 mg injection subcutaneous every 4 weeks for 52 weeks

    Biological: barzolvolimab

  • Experimental
    barzolvolimab 300 mg

    barzolvolimab 300 mg injection subcutaneous every 8 weeks for 52 weeks

    Biological: barzolvolimab

  • Experimental
    Placebo then barzolvolimab 150 mg

    Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 150 mg injection subcutaneous every 4 weeks for 36 weeks

    Biological: barzolvolimab · Drug: Matching Placebo

  • Experimental
    Placebo then barzolvolimab 300 mg

    Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 300 mg injection subcutaneous every 8 weeks for 36 weeks

    Biological: barzolvolimab · Drug: Matching Placebo

Interventions

  • Biologicalbarzolvolimab

    Subcutaneous Administration

    Also known as: CDX-0159

  • DrugMatching Placebo

    Subcutaneous Administration

06

What researchers measure

Primary outcomes

  1. Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)

    Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS). UAS7 is the sum of the itch severity score measured over 7 days (ISS7) and the hives severity score measured over 7 days (HSS7). The possible range of UAS7 is 0 - 42. Itch severity score (ISS) is on a scale of 0 - 3. 0 = None 1. = mild (present, but not annoying or troublesome) 2. = moderate (troublesome, but does not interfere with normal daily activity or sleep) 3. = intense (severe itch, which is sufficiently troublesome to interfere with normal daily activity or sleep) Hives severity score (HSS) is on a scale of 0 - 3. 0 = None 1. = less than 20 hives 2. = between 20 and 50 hives 3. = greater than 50 hives

    Time frame: From baseline to Day 85 (Week 12)

Secondary outcomes

  1. Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)

    ISS7 is derived by adding up the daily scores over 7 days. The possible range of the weekly score is 0 -21.

    Time frame: From baseline to Day 85 (Week 12)

  2. Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)

    HSS7 is derived by adding up the daily scores over 7 days. The possible range of the weekly score is 0 -21.

    Time frame: From baseline to Day 85 (Week 12)

  3. Mean change from baseline to Week 12 of AAS7 (Angioedema Activity Score)

    AAS captures the presences of swelling over the last 24 hours and rates the severity with 5 questions. The possible range of the weekly score is 0 - 105.

    Time frame: From baseline to Day 85 (Week 12)

07

Study locations

56 sites
  • Clinical Research Center of Alabama dba Allervie Clinical Research
    Birmingham, Alabama 35249, United States
  • Medical Research of Arizona
    Scottsdale, Arizona 85251, United States
  • Little Rock Allergy & Asthma CRC
    Little Rock, Arkansas 72205, United States
  • Kern Research, Inc
    Bakersfield, California 93301, United States
  • Allergy & Asthma Consultants
    Redwood City, California 94063, United States
  • IMMUNOe Research Centers
    Centennial, Colorado 80112, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Allergy & Asthma Specialists, PSC
    Owensboro, Kentucky 42301, United States
  • Institute for Asthma and Allergy
    Chevy Chase, Maryland 20815, United States
  • Chesapeake Clinical Research
    White Marsh, Maryland 21162, United States
  • Respiratory Medicine Research Institute of Michigan, PLC
    Ypsilanti, Michigan 48197, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Montefiore Medical Center/Subspeciality-Allergy and Immunology
    Bronx, New York 10461, United States
  • "Diagnostic Consultative Center Pulmed" EOOD
    Plovdiv, 4002, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD
    Plovdiv, 4002, Bulgaria
  • Outpatient clinic for individual practice for specialized outpatient medical care in allergology-Doctor Thalat Sally Cholak EOOD
    Razgrad, 7200, Bulgaria
  • Medical Center Iskar EOOD Office of Clinical Allergology
    Sofia, 1504, Bulgaria
  • Medical Center "SYNEXUS SOFIA", EOOD
    Sofia, 1784, Bulgaria
  • Vahlberg & Pild Clinic
    Tallinn, 10134, Estonia
  • Healthy Future
    Tbilisi, 0119, Georgia
  • Center of Allergy and Immunology
    Tbilisi, 0159, Georgia
  • Multiprofile Clinic Consilium Medulla
    Tbilisi, 0186, Georgia
  • LMU Klinikum - Klinik und Poliklinik für Dermatologie und Allergologie DASZ-Dermato-Allergologisches Studien Zentrum
    München, Bayern 80337, Germany
  • Universitaetsklinikum Giessen u. Marburg GmbH
    Marburg, Hessen 35043, Germany
  • Hannover Medical University
    Hannover, Niedersachsen 30625, Germany
  • Klinikum Oldenburg gGmbH - Klinik f. Dermatologie u. Allergologie
    Oldenburg, Niedersachsen 26133, Germany
  • Universitätsklinikum Düsseldorf - Dermatologie
    Düsseldorf, Nordrhein-Westfalen 40225, Germany
  • Universitätsklinikum Münster Klinik u. Poliklinik f. Dermatologie
    Münster, Nordrhein-Westfalen 48149, Germany
  • Universitätsklinikum Dresden
    Dresden, Sachsen 1307, Germany
  • Universitätsklinikum Schleswig-Holstein - Zentrum für entzündliche Hauterkrankunge
    Kiel, Schleswig-Holstein 24105, Germany
  • Charite - Institute of Allergology IFA Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Universitätsklinikum Heidelberg - Dermatologie
    Heidelberg, 69120, Germany
  • Semmelweis Egyetem, ÁOK, Bőr-, Nemikórtani és Bőronkológiai Klinika
    Budapest, 1085, Hungary
  • Debreceni Egyetem, ÁOK és KK, Bőrgyógyászati Tanszék és Bőrgyógyászati Klinika
    Debrecen, 4032, Hungary
  • Allergo-Derm Bakos Kft. Bőrgyógyászati Magánrendelő
    Szolnok, 5000, Hungary
  • Óbudai Egészségügyi Centrum Kft.
    Zalaegerszeg, 8900, Hungary
  • Centrum Medyczne Plejady
    Krakow, 30-363, Poland
  • Malopolskie Centrum Alergologii
    Krakow, 31-624, Poland
  • Uniwersytecki Szpital Kliniczny nr 1 w Lodzi
    Lodz, 90-153, Poland
  • Luxderm Specjalistyczny Gabinet Dermatologiczny Prof. Doroty Krasowskie
    Lublin, 20-573, Poland
  • Uniwersytecki Szpital Kliniczny w Opolu, Pododdział Chorób Wewnętrznych i Alergologii
    Opole, 45-401, Poland
  • Medicome Sp. z o.o.
    Oświęcim, 21-600, Poland
  • Medicover Integrated Clinical Services Sp. Z.o.o.
    Torun, 87-100, Poland
  • Klinika Ambroziak sp. z o.o.
    Warsaw, 02-953, Poland
  • Iatros International
    Bloemfontein, Free State 9324, South Africa
  • WorthWhile Clinical Trials
    Benoni, Gauteng 1500, South Africa
  • Newtown Clinical Research
    Johannesburg, Gauteng 2113, South Africa
  • Ubuntu Clinical Research
    Lenasia, Gauteng 1827, South Africa
  • FCRN Clinical Trial Centre Vaal Triangle
    Vereeniging, Gauteng 1935, South Africa
  • Synapta Clinical Research
    Durban, KwaZulu-Natal 4001, South Africa
  • Dr Pj Sebastian
    Durban, KwaZulu-Natal 4092, South Africa
  • The University of Cape Town - Lung Institute
    Cape Town, 7700, South Africa
  • Hospital General Universitario de Alicante
    Alicante, 3010, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital Bellvitge
    Barcelona, 8907, Spain
  • Universidad de Navarra
    Madrid, 28027, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Sep 2023, 16 months.

Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2022
First posted
May 10, 2022
StartActual
May 19, 2022
Primary completionActual
Sep 28, 2023
CompletionActual
Dec 20, 2024
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05368285
Responsible party
Sponsor
First posted
May 10, 2022
Start date
May 19, 2022
Primary completion
Sep 28, 2023
Completion
Dec 20, 2024
Last update
Mar 26, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Barzolvolimab

Start the discussion